Oncology Reporter_Volume 3_Issue 4_September 2022
Document ID: SC-VN-02599 | Author:
Boehringer Ingelheim
Boehringer Ingelheim
- Tính hiệu quả
- TATA23||RWE JAPAN IN ELDER- NEJ027
- HIGHLIGHTS FROM THE 2019 DISCUSSIONS IN SCIENTIFIC UPDATES (DSU) IN LUNG CANCER
- SH - James Yang Oct'2019 (MIMs)
- RWE South Korea
- RWE Singapore
- RWE Uncommon (TW & SK)
- Realgido
- AFATINIB is widely used across Asia in the real world
- Subsequent therapy after first-line AFATINIB failure can extend survival in countries with optimized cancer care
- Encouraging OS in patients who receive 3rd generation TKI after AFATINIB
- Higher in-vitro sensitivity of common EGFR mutations to AFATINIB translates to improved tumor responses in NSCLC
- AFATINIB- Osimertinib sequential therapy allows patients to stay longer on chemotherapy-free treatment
- AFATINIB followed by 3rd generation TKIs can be a reasonable choice for sequencing
- AFATINIB significantly reduces the relative risk in disease progression or death vs gefitinib in NSCLC
- AFATINIB efficacy in PFS, OS and response rates is consistent in the real world practice
- AFATINIB effectiveness in Taiwan real world clinical practice is consistent with RCTs
- AFATINIB delays onset and risk of CNS progression in patients with or without brain metastasis
- AFATINIB effectiveness in PFS, OS and intracranial response in brain metastases as demonstrated in the real world practice
- AFATINIB showed high potency and efficacy against NSCLC with uncommon EGFR mutations
- Asian real world evidence support use of AFATINIB in uncommon mutations
- Robust TTF improvement and tumor response with first-line AFATINIB in most NSCLC patients with uncommon EGFR mutations
- CNS effectiveness of 1st/2nd generation EGFR TKIs analyzed in Korea
- RESET study showed the feasibility of sequential treatment in patients with EGFR-mutated advanced NSCLC, maximizing sustained clinical benefit and minimizing exposure to chemotherapy
- First-line treatment with AFATINIB associated with longer OS in patients with EGFR mutation positive NSCLC. RWE from Chen Kung University, Taiwan
- AFATINIB offers EGFR-mutant NSCLC patients the opportunity of a treatment sequence that could help maximise time on targeted treatment and defer the need for chemotherapy: Sequential Cohort of UpSwinG study
- AFATINIB showed encouraging effectiveness in a broad NSCLC patient population including those with brain metastases or tumors harboring uncommon EGFR mutations – Real world evidence from South Korea
- Combined analysis of 2 non-interventional studies GioTag1 and UpSwinG2 showed encouraging activity in Asian Patients with EGFR M+ NSCLC3
- Totality outcome of AFATINIB sequential treatment in patients with EGFR M+ NSCLC in South Korea
- Tính an toàn
- Sự kiện